

BioSpect


the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Metropolis Healthcare introduces advanced blood-based Alzheimer's screening

27 April 2026 | News

Blood-based biomarker testing is emerging as a significant advancement in Alzheimer's diagnostics



Metropolis Healthcare has announced the launch of an advanced blood-based test designed to support earlier detection and more informed clinical decisions in Alzheimer's disease.

Alzheimer's disease (AD) is defined by its unique neuropathologic findings; hence diagnosis is based on clinical context, neuroimaging findings, and presence of accurate biomarkers in the intended population by which AD staging is done. Alzheimer's disease remains significantly underdiagnosed in its early stages, particularly among individuals over the age of 50, where cognitive decline is often overlooked or misattributed.

Metropolis' newly introduced blood-based test enables minimally invasive screening through a simple blood sample, allowing clinicians to assess the likelihood of Alzheimer's-related changes and guide next steps in care. This approach aligns with 2025 clinical practice recommendations from the Alzheimer's Association, which support the use of blood-based biomarkers such as pTau217 and the β -amyloid 1–42 ratio in individuals with cognitive impairment.

By identifying key disease-related markers, it provides a more convenient alternative to traditional diagnostic approaches such as PET scans or cerebrospinal fluid (CSF) testing. Backed by strong clinical evidence, including diagnostic accuracy of over 90% and strong alignment with amyloid PET imaging, the test provides reliable risk assessment.

The test can be used as an initial step in the clinical evaluation process. Based on the results, doctors can determine whether more advanced tests, such as PET scans or CSF analysis, are required, enabling timely decisions and appropriate care.

With this launch, Metropolis offers one of the most comprehensive Alzheimer's diagnostic pathways in India, spanning early blood-based screening, confirmatory CSF testing, and genetic risk assessment, including APOE genotyping. This integrated approach enables clinicians to access a complete diagnostic pathway within a single network, supporting coordinated and efficient patient management.